Literature DB >> 17462991

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.

Selina Khan1, Martijn S Bijker, Jimmy J Weterings, Hans J Tanke, Gosse J Adema, Thorbald van Hall, Jan W Drijfhout, Cornelis J M Melief, Hermen S Overkleeft, Gijsbert A van der Marel, Dmitri V Filippov, Sjoerd H van der Burg, Ferry Ossendorp.   

Abstract

Covalent conjugation of Toll-like receptor ligands (TLR-L) to synthetic antigenic peptides strongly improves antigen presentation in vitro and T lymphocyte priming in vivo. These molecularly well defined TLR-L-peptide conjugates, constitute an attractive vaccination modality, sharing the peptide antigen and a defined adjuvant in one single molecule. We have analyzed the intracellular trafficking and processing of two TLR-L conjugates in dendritic cells (DCs). Long synthetic peptides containing an ovalbumin cytotoxic T-cell epitope were chemically conjugated to two different TLR-Ls the TLR2 ligand, Pam(3)CysSK(4) (Pam) or the TLR9 ligand CpG. Rapid and enhanced uptake of both types of TLR-L-conjugated peptide occurred in DCs. Moreover, TLR-L conjugation greatly enhanced antigen presentation, a process that was dependent on endosomal acidification, proteasomal cleavage, and TAP translocation. The uptake of the CpG approximately conjugate was independent of endosomally-expressed TLR9 as reported previously. Unexpectedly, we found that Pam approximately conjugated peptides were likewise internalized independently of the expression of cell surface-expressed TLR2. Further characterization of the uptake mechanisms revealed that TLR2-L employed a different uptake route than TLR9-L. Inhibition of clathrin- or caveolin-dependent endocytosis greatly reduced uptake and antigen presentation of the Pam-conjugate. In contrast, internalization and antigen presentation of CpG approximately conjugates was independent of clathrin-coated pits but partly dependent on caveolae formation. Importantly, in contrast to the TLR-independent uptake of the conjugates, TLR expression and downstream TLR signaling was required for dendritic cell maturation and for priming of naïve CD8(+) T-cells. Together, our data show that targeting to two distinct TLRs requires distinct uptake mechanism but follows similar trafficking and intracellular processing pathways leading to optimal antigen presentation and T-cell priming.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462991     DOI: 10.1074/jbc.M701705200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

Review 1.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

2.  Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.

Authors:  Colin de Haar; Maud Plantinga; Nina Jg Blokland; Niek P van Til; Thijs Wh Flinsenberg; Viggo F Van Tendeloo; Evelien L Smits; Louis Boon; Lotte Spel; Marianne Boes; Jaap Jan Boelens; Stefan Nierkens
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

3.  Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells.

Authors:  Kuan-Yin Shen; Ying-Chyi Song; I-Hua Chen; Chih-Hsiang Leng; Hsin-Wei Chen; Hui-Ju Li; Pele Chong; Shih-Jen Liu
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

4.  Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells.

Authors:  Hongwei Zhang; Hai Hong; Demin Li; Shiwu Ma; Ying Di; Adam Stoten; Neil Haig; Katalin Di Gleria; Zhanru Yu; Xiao-Ning Xu; Andrew McMichael; Shisong Jiang
Journal:  J Biol Chem       Date:  2009-02-04       Impact factor: 5.157

5.  Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity.

Authors:  Nadine van Montfoort; Marcel G Camps; Selina Khan; Dmitri V Filippov; Jimmy J Weterings; Janice M Griffith; Hans J Geuze; Thorbald van Hall; J Sjef Verbeek; Cornelis J Melief; Ferry Ossendorp
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-03       Impact factor: 11.205

Review 6.  A peptide's perspective on antigen presentation to the immune system.

Authors:  Jacques Neefjes; Huib Ovaa
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

7.  Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.

Authors:  Kathrin Kastenmüller; Ulrike Wille-Reece; Ross W B Lindsay; Lauren R Trager; Patricia A Darrah; Barbara J Flynn; Maria R Becker; Mark C Udey; Björn E Clausen; Botond Z Igyarto; Daniel H Kaplan; Wolfgang Kastenmüller; Ronald N Germain; Robert A Seder
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

8.  Naive CD4+ T Cells Carrying a TLR2 Agonist Overcome TGF-β-Mediated Tumor Immune Evasion.

Authors:  Mohsen Ibrahim; Davide Scozzi; Kelsey A Toth; Donatella Ponti; Daniel Kreisel; Cecilia Menna; Elena De Falco; Antonio D'Andrilli; Erino A Rendina; Antonella Calogero; Alexander S Krupnick; Andrew E Gelman
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

9.  Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.

Authors:  Jasper G van den Boorn; Debby Konijnenberg; Esther P M Tjin; Daisy I Picavet; Nico J Meeuwenoord; Dmitri V Filippov; J P Wietze van der Veen; Jan D Bos; Cornelis J M Melief; Rosalie M Luiten
Journal:  PLoS One       Date:  2010-05-13       Impact factor: 3.240

10.  The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation.

Authors:  D Tien Nguyen; Lot de Witte; Martin Ludlow; Selma Yüksel; Karl-Heinz Wiesmüller; Teunis B H Geijtenbeek; Albert D M E Osterhaus; Rik L de Swart
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.